NCT07357675尚未招募3 期
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
EBI Anti Sepsis BV6 个研究点 分布在 4 个国家目标入组 300 人开始时间: 2026年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 300
- 试验地点
- 6
- 主要终点
- Required postoperative hospital length of stay
研究概览
简要总结
EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future.
This is a Phase III trial. It will take place in multiple locations and will follow a double-blind, randomized, placebo-controlled clinical design, meaning neither doctors nor participants will know whether they receive EA-230 or placebo during the trial. Assignment to EA-230 or placebo occurs by chance, like throwing dice. The total duration of the trial, including medical check-ups, will be approximately 71 days. There is a total of 10 visits, including a screening-, a pre-operative-, and 2 remote visits. 7 of these visits are during your stay at the hospital.
详细描述
The sites and vendor have been selected, and no further engagement regarding acquisition will be considered.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥18 years, both male and female.
- •Patients scheduled for elective on-pump CABG with at least 3 bypasses, with or without valve replacement.
- •Willing and able to give written informed consent.
排除标准
- •Patients undergoing non-elective on-pump CABG (i.e., emergency surgery). Emergency surgery is defined as planned surgery within 24 hours of diagnosis.
- •Cardiogenic shock or hemodynamic instability that requires inotropes, vasopressors, or other mechanical devices, such as an intra-aortic balloon counter-pulsation (IABP), within 24 hours prior to surgery.
- •Use of a left ventricular assist device (LVAD), or intra-aortic balloon pump or other cardiac devices, within 7 days prior to surgery.
- •A requirement for any of the following within 7 days prior to surgery: defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, or other forms of mechanical circulatory support.
- •Required cardiopulmonary resuscitation within 14 days prior to cardiac surgery.
- •Known chronic liver disorder with Child-Pugh C classification.
- •Confirmed or treated endocarditis requiring antimicrobial or antiviral treatment within 30 days prior to surgery or other current active infection requiring antimicrobial or antiviral treatment within 14 days prior to surgery.
- •Ongoing sepsis (as defined by SEPSIS-3) within 2 weeks of screening or, in the opinion of the investigator, an untreated clinically significant infection (viral or bacterial) prior to or at Screening and before randomization.
- •Immuno-compromised patients, as self-reported or as observed in medical records, including patients:
- •with solid organ transplantation.
- •known to be positive for human immunodeficiency virus (HIV).
- •that use immunosuppressive drugs or have received recent chemotherapy, at the discretion of the Investigator and including patients;
- •i. with active malignancy who have undergone chemotherapy within 30 days prior to trial entry.
- •ii. receiving chronic corticosteroid treatment equivalent to a prednisone dose of 10 mg or higher per day, within 30 days prior to trial entry, or an equivalent dose of another corticosteroid or any other anti-inflammatory or inflammation-suppressing medications such as interleukin blockers, methotrexate or similar therapies. Non-Steroidal Anti-Inflammatory Drugs are not exclusionary.
- •Patients with hematological disorders (known disorders from myeloid and/or lymphoid origin, leucopenia (both active and in remission)).
- •Known severe renal disease requiring dialysis, or a known estimated Glomerular Filtration Rate (eGFR) prior to admission of < 20 ml/min/1.73 m
- •Previous receipt of EA-
- •Known hypersensitivity to the IMP.
- •Use of any investigational drug within 1 month or 5 half-lives of said investigational drug (whichever is longer) prior to IMP administration in this trial. Participation in an observational clinical trial is not exclusionary.
- •Women who are pregnant, breastfeeding or planning to become pregnant during the trial or within 28 days after IMP administration (WOCBP must have a negative pregnancy test prior to entry into the trial).
- •Female patients of childbearing potential who are not willing/able to use adequate contraception and refrain from donating ova from enrolment and up to 28 days after IMP administration (contraceptive requirements are detailed in Annex
- •Contraceptive Guidance).
- •Male patients who are not willing/able to use adequate contraception (if their partners is of childbearing potential) and refrain from donating sperm from enrolment and up to 28 days after IMP administration (contraceptive requirements are detailed in Annex
- •Contraceptive Guidance).
- •Inability to personally provide written informed consent.
- •Known or suspected of not being able to comply with the trial protocol, at the discretion of the Investigator.
- •Any other condition which, in the Investigator's opinion, will interfere with completion of the trial.
- •Being an employee of the Investigator or trial site with direct involvement in the proposed trial or other studies under the direction of that Investigator or trial site or being a family member of an employee of the Investigator with direct involvement in the proposed trial.
结局指标
主要结局
Required postoperative hospital length of stay
时间窗: Up to 28 days
Median postoperative duration, from the moment of first incision until the time when a patient is eligible to be discharged from the hospital.
次要结局
- the effect of EA-230 on the duration of moderate and severe POCs(Up to 28 days)
- Hemodynamic stability via Net fluid balance(Up to 2 days (48 hours) after start of surgery (first incision))
- Hemodynamic stability via VIS score(Up to 2 days (48 hours) after start of surgery (first incision))
- Required postoperative ICU length of stay(Up to 28 days)
- Actual postoperative ICU and hospital length of stay(Up to 28 days)
- Blood plasma levels of EA-230 in microgram per liter (µg/L)(Up to 4 hours after IMP administration (on Day 1))
- Safety assessment of EA-230(Up to 28 days)
研究者
研究点 (6)
Loading locations...
相似试验
Enrolling By Invitation
不适用
Essential Amino Acid Supplementation in Adult Spinal Deformity PatientsNCT07341399University of Arkansas20
尚未招募
不适用
The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal Gastric Cancer.Stomach NeoplasmsAdenocarcinoma - Gastroesophageal Junction (GEJ)Gastroesophageal Junction CancerNCT07260461First Affiliated Hospital of Wenzhou Medical University120
招募中
不适用
Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral ArteryNCT07347665Hyogo Medical University200
招募中
3 期
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisNCT07321093Biocad292
尚未招募
2 期
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNCT07301229Shanghai Henlius Biotech100